Nxera Pharma Co., Ltd. (SOLTF)

USD 6.75

(-0.88%)

Market Cap (In USD)

606.83 Million

Revenue (In USD)

12.76 Billion

Net Income (In USD)

-7.19 Billion

Avg. Volume

34.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
6.75-13.43
PE
-
EPS
-
Beta Value
0.626
ISIN
JP3431300007
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Christopher Cargill
Employee Count
-
Website
https://soseiheptares.com
Ipo Date
2013-09-04
Details
Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of HTL0022562, a calcitonin gene related peptide antagonist, which is in Phase I clinical study; HTL0016878 for neurological diseases; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; and TMP301 and BHV3100 for neurological disorders, which is in clinical trials. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.